Brickell Biotech Shares Surge After Offloading Late-Stage Asset To Australia-Based Firm

  • Brickell Biotech Inc BBI agreed to sell sofpironium bromide rights to Australia-based Botanix Pharmaceuticals Limited.
  • Brickell will receive upfront and potential near-term regulatory milestone payments over the next 18 months of up to $9 million.
  • Brickell also is eligible to receive additional milestone payments of up to $168 million and tiered earn-out payments ranging from high-single digits to mid-teen digits on net sales of sofpironium bromide gel.
  • Read Next: Brickell Biotech, Carna Biosciences Ink Licensing Pact For STING inhibitors.
  • Sofpironium bromide, a retrometabolically-designed new chemical entity, belongs to a class of medications called anticholinergics. 
  • Sofpironium bromide gel, 15% recently completed a U.S. Phase 3 program for primary axillary hyperhidrosis or excessive underarm sweating. 
  • Brickell was on track to submit a marketing application to the FDA in mid-2022.
  • Brickell will provide consulting services to Botanix through submission and potential U.S. approval for sofpironium bromide gel, 15%.
  • Price Action: BBI shares are up 24.70% at $0.29 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechM&ANewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!